 |
Ask Doctor DawnAn hour of medical questions, answers, debate, dialogue, discussion, & health in the news. Author: Dr. Dawn Motyka - JivaMedia.com
Answers to your medical questions and health topics in the news. Language: en-us Genres: Alternative Health, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Bright Light Therapy for Non-Seasonal Depression, Red Light Photobiomodulation of Mitochondria, Daylight Saving Time Mortality, Acetaminophen Blunting Social Pain, Sucralose Safety, and a new ALS therapy
Friday, 23 October, 2026
Broadcast from KSQD, Santa Cruz on 10-22-2026: Bright light therapy at 10,000 lumens or more (via light box or visor) has moderate-quality meta-analysis evidence as an effective primary or adjuvant treatment for non-seasonal depressive disorder—not just the winter-blues form. A study of 104 patients labeled with sulfa allergy found only four reacted (all mild) when given an oral challenge, and Dr. Dawn notes the PEN-FAST tool helps identify mislabeled patients—worth revisiting because sulfa antibiotics are mitochondria-sparing, unlike many others. Nighttime pain and itch flares occur because descending inhibition from the spinal cord drops in darkness, with the suprachiasmatic nucleus using vasoactive intestinal peptide to modulate this circadian pattern. Red light at 660 nm (skin) and 850 nm (deeper tissue) is absorbed by mitochondrial cytochrome c oxidase, boosting ATP production and antioxidant response—with demonstrated benefits for chemotherapy-induced oral ulcers, retinal color-contrast vision in adults over 40, and even 7.5% lower post-meal glucose spikes. A Birmingham neurosurgeon is developing silicone-embedded LED implants to deliver red light directly to brain and spinal cord injury sites, aiming to rescue stunned-but-not-dead neurons. Cell culture and rat studies show 20% reductions in cell death. A caller asks about daylight saving versus standard time; Dr. Dawn confirms the spring-forward shift increases deaths from strokes, heart attacks, and traffic accidents due to acute stress and inflammation, with federal law currently preventing states from unilaterally stopping the switch. A trial of 1,000 mg daily acetaminophen for three weeks reduced self-reported social pain from exclusion, bullying, and teasing, with fMRI showing decreased activity in the dorsal anterior cingulate cortex and anterior insula — though it also blunts empathy for others and positive emotional response. A sub-study on workplace bullying identified two specific microRNAs whose dampening of pro-inflammatory mediators is disrupted by chronic social defeat stress, elevating corticosteroids and reactive oxygen species system-wide. Dr. Dawn critiques meta-analysis as a blunt tool subject to publication bias and inappropriate pooling — combining data on genetically disparate populations (e.g., Korean men, Scandinavians, North Africans) yields findings that are statistically true but not generalizable, and PhD theses may be more rigorously vetted than typical peer-reviewed papers. An emailer asks whether Splenda damages DNA; Dr. Dawn explains the concern involves a manufacturing impurity (sucralose-6-acetate) at concentrations requiring 4-5 sweetened beverages daily, that 2026 commercial-grade sucralose testing showed no mutation or chromosome damage, but artificial sweeteners do increase appetite by priming digestion without delivering calories. Dr. Dawn advises on using AI chatbots for health advice: always verify sources (sometimes fabricated), ask neutral questions ("pros and cons of X") rather than leading ones, opt out of Google's AI with "-ai" at the search query's end, and use incognito browsing for sensitive health searches to avoid tracking. The first antisense oligonucleotide therapy for ALS targets the CHCHD10 gene (whose protein enables mitochondrial energy production). A patient receiving three 50 mg doses over a year showed stable cognition, dropping neurofilament light chain to reference range, and some improvement, offering hope for the ~10% of ALS patients with targetable genetic mutations.
